Paragon Genomics

Paragon Genomics is a precision medicine company headquartered in the San Francisco Bay Area. Its patented targeted sequencing technologies — CleanPlex® DNA, CleanPlex® RNA and CleanPlex® UMI — provide solutions for precision oncology, infectious disease testing, inherited disease testing, public health disease surveillance, single cell analysis, molecular breeding and other applications. The company states that its technologies and products have been adopted by thousands of sequencing labs globally, and that it can rapidly produce customized sequencing assays for researchers, testing labs and biopharma precision medicine projects. It also offers OEM services, designing, developing and manufacturing custom amplicon NGS panels and reagents under partner brands.

Paragon Genomics is a precision medicine company headquartered in the San Francisco Bay Area. Its mission is to provide high-quality target enrichment solutions to the genomics community to advance precision medicine and research. The company's patented targeted sequencing technologies — CleanPlex® DNA, CleanPlex® RNA and CleanPlex® UMI — provide solutions to precision oncology, infectious disease testing, inherited disease testing, public health disease surveillance, single cell analysis, molecular breeding and other applications. Paragon Genomics states that its technologies and products have been adopted by thousands of sequencing labs globally. Its leadership team graduated from the California Life Sciences Institute's (CLSI) Spring 2016 FAST Advisory Program and was accepted into the StartX Fall 2016 Accelerator Program. In September 2019, the company established a subsidiary to market its CleanPlex® NGS target enrichment solutions in China. In March 2020, it introduced the CleanPlex® SARS-CoV-2 NGS Panel for research and surveillance of COVID-19 coronavirus. In July 2025, Paragon Genomics and Genecast announced a global partnership to advance precision oncology.

Provider of high-quality target enrichment solutions to the genomics community to advance precision medicine and research.

• CleanPlex® DNA

  Patented targeted sequencing technology.

• CleanPlex® RNA

  Patented targeted sequencing technology.

• CleanPlex® UMI

  Patented targeted sequencing technology.

• CleanPlex® SARS-CoV-2 NGS Panel

  Panel for research and surveillance of COVID-19 coronavirus.

• CleanPlex® CFTR Panel

  Panel introduced at AMP 2019 Annual Meeting.

• CleanPlex® Hereditary Cancer Panel V2

  Panel introduced at the American Society for Human Genetics 2019 Annual Meeting.

• CleanPlex® Emerging Variant Add-on V2

  Add-on for enhanced identification of Omicron and emerging SARS-CoV-2 variants.

1. 1CleanPlex® Multiplex PCR-Based Target Enrichment and Library Preparation Kits for Amplicon Sequencingparagongenomics.com
2. 2Company Corporate Profile | Paragon Genomicsparagongenomics.com
3. 3OEM Brand Partnerships | Paragon Genomicsparagongenomics.com
4. 4News Updates | Paragon Genomicsparagongenomics.com
5. 5Paragon Genomics Introduces CleanPlex® CFTR Panel And Unveils New Fusion Detection Methods At AMP 2019 Annual Meetingprnewswire.com